



## REGENXBIO to Present at The Chardan 3rd Annual Genetic Medicines Conference

September 30, 2019 07:00 AM EDT

ROCKVILLE, Md., Sept. 30, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV<sup>®</sup> Technology Platform, today announced that it will present at the Chardan 3<sup>rd</sup> Annual Genetic Medicines Conference on Monday, October 7, 2019, at The Westin New York Grand Central, NY:

**Panel:** *Emerging Disease Areas in Gene Therapy*; Monday, October 7, 2019 at 9:30 a.m. ET

**Fireside Chat:** Monday, October 7, 2019 at 12:00 p.m. ET.

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the fireside chat webcast will be available on the same website for approximately 30 days following the presentation.

### About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

REGENXBIO's NAV<sup>®</sup> Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

### CONTACT:

Tricia Truehart  
Investor Relations and Corporate Communications  
347-926-7709  
[ttruehart@regenxbio.com](mailto:ttruehart@regenxbio.com)

### Investors:

Heather Savelle, 212-600-1902  
[heather@argotpartners.com](mailto:heather@argotpartners.com)

### Media:

David Rosen, 212-600-1902  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-chardan-3rd-annual-genetic-medicines-conference-300927368.html>

SOURCE REGENXBIO Inc.